TriReme Medical Signs Distribution Agreement with Cordis Corporation

PLEASANTON, Calif., and SINGAPORE, Feb. 19, 2014 /PRNewswire/ -- TriReme Medical LLC, a subsidiary of Singapore based QT Vascular Ltd., announced today that it has signed a broad distribution agreement with Cordis Corporation for the exclusive distribution of its unique Chocolate® PTA Balloon Angioplasty Catheter, with an option for additional TriReme portfolio products. This agreement will expand TriReme's commercial footprint and allow the company to focus on its promising development pipeline.

"Cordis has an unparalleled track record in creating and building new and innovative product categories that have dramatically changed and improved clinical practice. We are honored to partner with Cordis and look forward to our collaboration," said Dr. Eitan Konstantino, President and CEO of TriReme.

The Chocolate® PTA Balloon Catheter, approved in the U.S. in December 2011, is a unique PTA balloon that is designed to allow for atraumatic dilatation in treating peripheral artery disease (PAD). The Chocolate® PTA Balloon Catheter is indicated for balloon dilatation of lesions in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries. Not for use in the coronary or cerebral vasculature. Its unique nitinol constraining structure creates uniform "pillows" that make contact with the vessel and "valleys" that allow for plaque modification and are designed to relieve stress upon inflation.

Data from the first 350 patients in the CHOCOLATE® BAR Registry were recently presented at the 2014 Leipzig Interventional Course (LINC) earlier this month. In this all-comers study that included many patients suffering from advanced atherosclerotic disease in their legs and patients at high risk of amputation (Rutherford 5 and 6, total occlusions, long and calcified lesions), the use of the Chocolate® PTA Balloon Catheter was associated with high rates of treatment success and limb preservation and very low rates of dissections and bail-out stenting.

"We are delighted to see TriReme gain this level of global recognition," stated Mr. Michael Kleine, board member of QT Vascular and former CEO of Biosensors International. "TriReme management has been building a valuable business by driving strong market adoption for its products backed with excellent clinical data."

About Peripheral Arterial Disease

Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide.¹

About TriReme Medical, LLC

TriReme, a subsidiary of Singapore based QT Vascular Ltd., is an emerging leader in the development and commercialization of next generation minimally invasive devices for the treatment of complex arterial disease. The company is focused on the US and the emerging Asian markets.

¹. "Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.

SOURCE TriReme Medical, LLC